CenterWatch releases new report examining Japan’s clinical trials market, the differences in the country’s approach to clinical research, and new government initiatives aimed at attracting big pharma to conduct simultaneous global clinical trials in Japan.

New government initiatives have helped to streamline drug review and approval processes, and sponsor companies have responded by including Japan in their global drug development programs more
Japan is participating in global drug development at historic levels; however, there is still work to be done there to sustain that growth.

Boston, MA (PRWEB) April 1, 2009 — In 2007, drug development in Japan, the world’s second largest pharmaceutical market, exploded six-fold over 2006 and should continue to grow, according to a new CenterWatch report released today, Japan: Opening the Door to Global Clinical Trials.

This comprehensive analysis, the fourth in a series of CenterWatch reports on global clinical research markets, takes a look at the reasons for Japan’s dramatic growth, the differences in the country’s approach to clinical research, and government initiatives to attract Big Pharma to conduct simultaneous global clinical trials in Japan.

“New government initiatives have helped to streamline drug review and approval processes, and sponsor companies have responded by including Japan in their global drug development programs more,” said Sara Gambrill, senior editor at CenterWatch and author of the report. “Japan is participating in global drug development at historic levels; however, there is still work to be done there to sustain that growth.”

This is an essential resource for any business seeking to better understand Japan’s clinical trials landscape and what to expect when conducting clinical research there.

To purchase Japan: Opening the Door to Global Clinical Trials, visit the CenterWatch bookstore at http://store.centerwatch.com.

About Sara Gambrill
Sara Gambrill is senior editor at CenterWatch and writes features about international and domestic clinical research industry trends regularly for The CenterWatch Monthly and CWWeekly. She has also written several special reports on clinical research markets, including Asia-Pacific and Central and Eastern Europe.

About CenterWatch
Founded in 1994, CenterWatch is a trusted source and global destination for clinical trials information for both professionals and patients. We provide proprietary data and information about clinical trials through a variety of newsletters, books, databases, and information services used by pharmaceutical and biotechnology companies, CROs, SMOs, and investigative sites involved in the management and conduct of clinical trials. CenterWatch was also the first Internet site to publish detailed information about active clinical trials that could be accessed by patients and their advocates. Today, we have one of the largest databases of clinical trials actively seeking patients on the Internet.

Related Health News:

1. Clinical Trials of the America’s Inc. Enters into Binding Letter of Intent with Next Fuels, Inc. CAREY, N.C., April 8 /PRNewswire-FirstCall/ — Clinical Trials of America Inc. (“Clinical Trials” of the “Company”) (OTC:CLLL) (BULLETIN BOARD: CLLL) announced that it has entered...
2. Chinese Colorectal Cancer Drug Market Will More Than Double by 2012 Modest Increase in Market Share Expected for Western Drug Companies, According to a Report from Decision Resources WALTHAM, Mass., April 13 /PRNewswire/ — Decision Resources,...
3. Frost & Sullivan Lauds Carl Zeiss Meditec for Dominating the OCT Market for Ophthalmic Applications MOUNTAIN VIEW, Calif., March 31 /PRNewswire/ — Based on its recent analysis of the optical technologies market, Frost & Sullivan recognizes Carl Zeiss Meditec with...
4. Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers LA JOLLA, Calif., April 8 /PRNewswire-FirstCall/ — Cordex Pharma, Inc. (OTC:CDXP) (BULLETIN BOARD: CDXP) announced today that it has agreed to collaborate with BG Medicine...
5. Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist Trial Will Evaluate Safety, Proof of Mechanism of a Potential Oral Antagonist for the Treatment of Asthma and COPD SAN DIEGO, April 20 /PRNewswire/ —...